AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9987142
Drug: Full-dose Mérieux
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose Mérieux BCG vaccine (lot E0650)
Trial: 9987142
Drug: Full-dose Mérieux
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose Mérieux BCG vaccine (lot E0624)
Trial: 9987142
Drug: Full-dose WHO-reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose WHO-reference vaccine (Tokyo strain 172)
Trial: 9987142
Drug: 1/10 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10 dose WHO-reference vaccine
Trial: 7489845
Drug: Lovastatin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (n = 16; mean dose 30.0 +/- 12.6 mg/day)
Trial: 2227746
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Ruscus extract (4 to 6 g of cream containing 64 to 96 mg Ruscus extract)
Trial: 2227746
Drug: Placebo (base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (base of the cream)
Trial: 29653541
Drug: TARGIT-IORT (single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TARGIT-IORT (single-dose intra-operative radiotherapy)
Trial: 26702749
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy (6 painting sessions)
Trial: 25456558
Drug: Setrobuvir 200
RxNorm normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setrobuvir 200 mg BID
Trial: 25456558
Drug: Setrobuvir 400
RxNorm normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setrobuvir 400 mg BID
Trial: 25456558
Drug: Setrobuvir 800
RxNorm normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setrobuvir 800 mg BID
Trial: 15340127
Drug: lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumiracoxib 400 mg/day
Trial: 9549655
Drug: (R)-ketoprofen 100
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (R)-ketoprofen 100 mg b.i.d.
Trial: 9549655
Drug: (R)-flurbiprofen 100
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (R)-flurbiprofen 100 mg b.i.d.
Trial: 9549655
Drug: racemic ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: racemic ketoprofen 100 mg b.i.d.
Trial: 9549655
Drug: paracetamol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paracetamol 1,000 mg b.i.d.
Trial: 7803063
Drug: Practice models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Practice models for applying the 1988 Adult Treatment Panel Guidelines
Trial: 31933034
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (12-week exercise programme, twice per week)
Trial: 29320589
Drug: Test Product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test Product (novel hyaluronic acid gel)
Trial: 29320589
Drug: Comparator (non‐animal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator (non‐animal stabilized hyaluronic acid gel)
Trial: 25018057
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (260 mg)
Trial: 8879603
Drug: beta-blocker +
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-blocker + diuretics
Trial: 10225478
Drug: calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcium antagonists
Trial: 2271853
Drug: Thiazide diuretics
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretics taken by 325 men for a mean of 11.9 years
Trial: 2271853
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive drugs taken by 53 men
Trial: 28369211
Drug: GSK3532795 5-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3532795 5-120 mg once daily for 10 days (Part A)
Trial: 28369211
Drug: GSK3532795 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3532795 40 mg or 80 mg once daily with atazanavir (ATV) ± ritonavir (RTV) for 28 days (Part B)
Trial: 28369211
Drug: GSK3532795 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3532795 40 mg or 120 mg once daily for 10 days (Part C)
Trial: 23722951
Drug: Real electroacupuncture
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real electroacupuncture (EA) twice weekly for 6 weeks
Trial: 23722951
Drug: Sham electroacupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture (EA) twice weekly for 6 weeks
Trial: 17519278
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with methotrexate (MTX)
Trial: 17519278
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with methotrexate (MTX)
Trial: 11159760
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g meat/day
Trial: 11159760
Drug: 240 g
RxNorm normalized name: aspirin 15.6 GM (240 grains) Oral Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 g meat/day
Trial: 11159760
Drug: 420 g
RxNorm normalized name: GLYCERIN 20 g in 420 g TOPICAL SOAP [Kojic Acid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 g meat/day
Trial: 11159760
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g meat/day
Trial: 11159760
Drug: 420 g
RxNorm normalized name: GLYCERIN 20 g in 420 g TOPICAL SOAP [Kojic Acid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 420 g meat/day for 40 days
Trial: 7697230
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination dry powder inhaler (Turbuhaler) containing terbutaline (250 micrograms) with budesonide (200 micrograms)
Trial: 11696921
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + irrigation with collagen gel containing 1% chlorhexidine (group 3)
Trial: 11696921
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + irrigation with collagen gel (group 2)
Trial: 2691317
Drug: Shosaiko-to (SST)
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shosaiko-to (SST) 5.4 g daily for 12 weeks
Trial: 2691317
Drug: Placebo 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5 g of SST for 12 weeks
Trial: 26955704
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion (0.05 mg · kg(‐1) · min(‐1) for 24 hours)
Trial: 15199073
Drug: telavancin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telavancin 7.5 mg/kg
Trial: 15199073
Drug: telavancin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telavancin 15 mg/kg
Trial: 15199073
Drug: moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moxifloxacin 400 mg (positive control)
Trial: 2886533
Drug: Latamoxef at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latamoxef at 6 g day‐1
Trial: 2886533
Drug: Latamoxef at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latamoxef at 3 g day‐1
Trial: 25439435
Drug: AKB‐9778 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKB‐9778 15 mg or more twice daily
Trial: 25439435
Drug: AKB‐9778 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKB‐9778 22.5 mg or more twice daily
Trial: 23972322
Drug: Any category
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any category of AREDS treatment
Trial: 18512710
Drug: Rituximab (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1,000 mg on days 1 and 15)
Trial: 21225699
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of anti‐CCP antibodies or RF
Trial: 21225699
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of RF or anti‐CCP antibodies and elevated IgG
Trial: 10753248
Drug: Spacer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spacer group (albuterol 600 microg by MDI with spacer)
Trial: 10753248
Drug: Nebulizer group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer group (2.5 mg albuterol by nebulizer)
Trial: 8884922
Drug: Oral intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of CoQ10
Trial: 1362841
Drug: Dithranol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol 2% ointment applied once daily for 8 weeks
Trial: 1362841
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied once daily for 8 weeks
Trial: 1362841
Drug: Dithranol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol treatment
Trial: 29782641
Drug: Epidural oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural oxycodone 0.1 mg·kg-1
Trial: 29782641
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone 0.1 mg·kg-1
Trial: 23137512
Drug: NT-proBNP guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP guided care aiming to reduce NT-proBNP values ≤1000 pg/mL
Trial: 20381658
Drug: DM treatment
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DM treatment intensification for suboptimal control (HbA(1c) 7% to 9%)
Trial: 20381658
Drug: DM treatment
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DM treatment intensification for poor control (HbA(1c) >9%)
Trial: 18431346
Drug: MC-1 250
RxNorm normalized name: MC-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC-1 250 mg/day
Trial: 18431346
Drug: MC-1 750
RxNorm normalized name: MC-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC-1 750 mg/day
Trial: 7737776
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg once daily for 3 months
Trial: 7737776
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg for 3 months
Trial: 2044924
Drug: 0.1N hydrochloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1N hydrochloric acid infusion
Trial: 2044924
Drug: Autologous duodenal
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous duodenal secretions infusion
Trial: 6291739
Drug: Daily radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily radiotherapy (5000 rad in 25 fractions in 5 weeks)
Trial: 6291739
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (hyperfractionation and daily regimens)
Trial: 6291739
Drug: Hyperfractionation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionation with chemotherapy
Trial: 25616431
Drug: Axitinib (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (in patients with prior sunitinib treatment)
Trial: 15964483
Drug: RTS,S/AS02A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02A vaccine at 10 microg
Trial: 15964483
Drug: RTS,S/AS02A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02A vaccine at 25 microg
Trial: 15964483
Drug: RTS,S/AS02A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02A vaccine at 50 microg
Trial: 11796658
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (Cr, 4 x 5 g/day, 4 days)
Trial: 11796658
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (Caf, 5 mg x kg(‐1) x day(‐1), 3 days)
Trial: 11796658
Drug: Acute caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute caffeine intake (ACaf, 5 mg/kg)
Trial: 2404843
Drug: Carboplatin administered
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered at 06.00
Trial: 2404843
Drug: Carboplatin administered
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered at 18.00
Trial: 7298477
Drug: Therapies (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies (specific types not detailed)
Trial: 31197861
Drug: Oral ferrous
RxNorm normalized name: ferrous fumarate Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ferrous sulphate (FeSulf)
Trial: 21640762
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg per day (AT group, n=52)
Trial: 17195236
Drug: CAT-192 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAT-192 (10 mg/kg)
Trial: 17195236
Drug: CAT-192 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAT-192 (5 mg/kg)
Trial: 17195236
Drug: CAT-192 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAT-192 (0.5 mg/kg)
Trial: 17195236
Drug: CAT-192 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAT-192 (all doses)
Trial: 12686786
Drug: 1 mg/h
RxNorm normalized name: fentanyl 0.1 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/h nimodipine
Trial: 12686786
Drug: 2 mg/h
RxNorm normalized name: nicotine 0.312 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/h nimodipine
Trial: 12686786
Drug: High-dose nimodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nimodipine
Trial: 10985616
Drug: Cetrorelix (LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrorelix (LHRH antagonist)
Trial: 10985616
Drug: Buserelin (LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin (LHRH agonist)
Trial: 9368162
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (brief course of steroids)
Trial: 1547059
Drug: Neostigmine 0.036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.036 mg kg‐1
Trial: 1547059
Drug: Neostigmine 0.071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.071 mg kg‐1
Trial: 1547059
Drug: Edrophonium 1.43
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 1.43 mg kg‐1
Trial: 3904908
Drug: diethylstilboestrol 3
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: diethylstilboestrol 3 mg/day
Trial: 3904908
Drug: estramustine 560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estramustine 560 mg/day
Trial: 27831636
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of dust mite drops, once per day, gradually increasing the dose to reach a high maintenance level.
Trial: 27831636
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of dust mite drops
Trial: 22541754
Drug: PF-00734200 10
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-00734200 10 mg single dose
Trial: 22541754
Drug: PF-00734200 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00734200 100 mg single dose
Trial: 22541754
Drug: PF-00734200 20
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-00734200 20 mg once daily for 6 days
Trial: 18384853
Drug: Weekly postoperative
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly postoperative pelvic floor muscle training (PFMT) (Treatment)
Trial: 15875528
Drug: Ciclesonide 640
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 640 microg twice daily
Trial: 15875528
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 880 microg twice daily
Trial: 10561630
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (6 g loading dose in 100 mL isotonic sodium chloride solution, followed by 2 g/h infusion for 3 hours at 125 mL/h)
Trial: 10561630
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution (100 mL isotonic sodium chloride solution, similar infusion rate)
Trial: 9046544
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment using specially designed compression pads, elevation of the injured foot (24 h), repeated elastic wrapping, early full weight-bearing and proprioceptive range-of-motion training (Group I, n = 46)
Trial: 9046544
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with an elastic bandage, partial weight bearing and crutches until pain subsided (Group II, n = 40)
Trial: 9046544
Drug: Functional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatment (Group I)
Trial: 9046544
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Group II)
Trial: 1989755
Drug: Dantrolene sodium
RxNorm normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dantrolene sodium (2 mg/kg body weight iv)
Trial: 6340700
Drug: pindolol (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol (standard medication)
Trial: 24819911
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose escalation scheme of dipyridamole
Trial: 24819911
Drug: Slow dose
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow dose escalation scheme of dipyridamole
Trial: 22802432
Drug: 2009 H1N1
RxNorm normalized name: influenza A virus A/California/7/2009 (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 H1N1 vaccine and seasonal TIV (TIV; split virion)
Trial: 18540726
Drug: Decisional Balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decisional Balance Scale administered via computerized and paper versions
Trial: 15785936
Drug: Ibuprofen co-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen co-treatment
Trial: 15785936
Drug: No ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No ibuprofen co-treatment (Control)
Trial: 8775645
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (0.5 g.kg‐1 body weight)
Trial: 8775645
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium carbonate, 0.5 g.kg‐1 body weight)
Trial: 22235525
Drug: Prototype medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype medication drawer (Drawer 2)
Trial: 22235525
Drug: Baseline medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline medication drawer (Drawer 1)
Trial: 19516186
Drug: Calcium Channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Channel Blockers (CCB)
Trial: 17410045
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2, day 1, every 3 weeks for eight cycles)
Trial: 17410045
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m2 for cycles 1 and 2) followed by Gemcitabine (1200 mg/m2, days 1 and 8, every 3 weeks for cycles 3 and 4, repeated for a total of eight cycles)
Trial: 3931467
Drug: Glyburide plus
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide plus insulin